SCHEMBL31700554

SCHEMBL31700554

N#Cc1cccc(S(=O)(=O)Nc2ccc3ocnc3c2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN2 P17706 7/20 0.64
▸ PTPN1 P18031 7/20 0.64
▸ PTPN5 P54829 7/20 0.64
▸ HSPD1 P10809 5/20 0.64
▸ HSPE1 P61604 5/20 0.64
▸ PGR P06401 1/20 0.53
▸ BRD1 O95696 1/20 0.52
▸ BRPF1 P55201 1/20 0.52
▸ BRD4 O60885 1/20 0.49
▸ GLO1 Q04760 1/20 0.48
▸ SLC40A1 Q9NP59 1/20 0.48
▸ KDM1A O60341 1/20 0.46
▸ MAOA P21397 1/20 0.46
▸ HTR6 P50406 1/20 0.45
▸ SGK1 O00141 2/20 0.45
▸ PIK3CD O00329 1/20 0.43
▸ TRIM24 O15164 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31701008 0.87 HSPD1 (0.61) PTPN2PTPN1PTPN5HSPD1HSPE1
SCHEMBL31700542 0.82 PTPN2 (0.61) PTPN2PTPN1PTPN5HSPD1HSPE1
SCHEMBL31702160 0.82 HSPD1 (0.61) PTPN2PTPN1PTPN5HSPD1HSPE1
SCHEMBL31700702 0.82 PTPN5 (0.61) PTPN2PTPN1PTPN5HSPD1HSPE1
SCHEMBL31702052 0.82 PTPN2 (0.61) PTPN2PTPN1PTPN5HSPD1HSPE1
SCHEMBL31701603 0.79 PTPN2 (0.64) PTPN2PTPN1PTPN5HSPD1HSPE1
SCHEMBL31701721 0.79 HSPD1 (0.64) PTPN2PTPN1PTPN5HSPD1HSPE1
SCHEMBL31700367 0.79 PTPN2 (0.64) PTPN2PTPN1PTPN5HSPD1HSPE1
SCHEMBL31700541 0.78 HSPD1 (0.64) PTPN2PTPN1PTPN5HSPD1HSPE1
SCHEMBL31701128 0.78 PTPN2 (0.64) PTPN2PTPN1PTPN5HSPD1HSPE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250319056-A1 METHODS FOR TREATING CANCER UNIV INDIANA TRUSTEES (US) 2025-10-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250319056-A1 METHODS FOR TREATING CANCER HSP90AB1, HSP90B1, HSP90AB2P PTPN2 2771/4885PTPN1 3070/4885PTPN5 2831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback